10.05.2016AC Immune lève 42,7 millions CHF lors du tour de financement EYou are hereNewsAC Immune lève 42,7 millions CHF lors du tour de financement E
trésorerie existantes, pour continuer à développer son pipeline clinique et préclinique de produits thérapeutiques et diagnostiques contre la maladie d’Alzheimer et des autres maladies neurodégénératives.
Find an actor
ILMAC Lausanne 201803.10.2018ILMAC Lausanne is the new platform for the chemical & life sciences community. The event will take place on 3 and 4...
Addex Pharma - recoit un financement de 1,2 M£Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the...
Med Discovery SATherapeutics & Diagnostics, Proteins / PeptidesMed Discovery is a Swiss biopharmaceutical company dedicated to the discovery and the development of highly specific treatments for uro-genital cancers.
Our strategy is to develop protein drugs based on the optimization of natural proteins involved in the regulation of biological pathways.
To achieve this we are leveraging a unique in-house expertise in kallikreins, the biggest class of human proteases, combined with an international network in clinical urology.
Our proprietary technology platform to produce protease inhibitors allows Med Discovery to target cancers or other diseases where there is a lack of specific treatment.
Using this approach, Med Discovery intends to become a leading research and development biotech company in the uro-genital field, developing products both in-house and with appropriate partners.